TG Therapeutics, Inc. $TGTX Stock: Intech Investment Management LLC Decreases Position

Intech Investment Management LLC decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 29.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 87,448 shares of the biopharmaceutical company’s stock after selling 37,198 shares during the period. Intech Investment Management LLC owned about 0.06% of TG Therapeutics worth $4,878,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Morse Asset Management Inc acquired a new position in shares of TG Therapeutics during the 3rd quarter worth $29,000. Bessemer Group Inc. boosted its position in shares of TG Therapeutics by 119.3% in the 3rd quarter. Bessemer Group Inc. now owns 290,660 shares of the biopharmaceutical company’s stock worth $16,213,000 after buying an additional 158,105 shares in the last quarter. Virtus Advisers LLC grew its stake in TG Therapeutics by 25.1% in the 3rd quarter. Virtus Advisers LLC now owns 9,138 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 1,836 shares during the last quarter. ACT Capital Partners L.P. acquired a new stake in TG Therapeutics in the 3rd quarter valued at about $13,231,000. Finally, Russell Investments Group Ltd. grew its stake in TG Therapeutics by 2.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 309,498 shares of the biopharmaceutical company’s stock valued at $17,264,000 after acquiring an additional 8,183 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Up 5.4%

TGTX stock opened at $66.12 on Thursday. The company has a 50 day moving average price of $57.20 and a two-hundred day moving average price of $45.84. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.75 and a current ratio of 4.50. The stock has a market capitalization of $9.99 billion, a P/E ratio of 100.18, a PEG ratio of 4.94 and a beta of 1.89. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $68.03.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The business had revenue of $259.94 million for the quarter, compared to analysts’ expectations of $245.47 million. During the same period in the prior year, the company earned $2.43 EPS. The company’s revenue for the quarter was up 60.8% compared to the same quarter last year. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 1.10 EPS for the current year.

Insider Buying and Selling

In related news, Director Laurence Charney sold 5,000 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares in the company, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 8.87% of the company’s stock.

Wall Street Analyst Weigh In

TGTX has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a report on Tuesday, September 1st. Zacks Research raised shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. B. Riley Financial raised their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Finally, Weiss Ratings upgraded TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $63.00.

Read Our Latest Research Report on TG Therapeutics

TG Therapeutics Profile

(Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Further Reading

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.